Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/26/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mary F. Fitzgerald

Wrong Dr. Mary F. Fitzgerald?

Executive Vice President of Respi...

Phone: +44 ***********  
Email: m***@***.com
Local Address:  United Kingdom
Company Description: Pulmagen Therapeutics is a privately held respiratory drug development company headquartered in Burnham, Bucks, UK. The company has developed a portfolio of...   more
Background

Employment History

Education

  • BSc , Pharmacology
    Bath University
  • Ph.D.
  • PhD
    Sunderland University
41 Total References
Web References
Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)
www.pieris.com [cached]
Mary Fitzgerald, Ph.D.
...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.
Management Team :: Pieris Pharmaceuticals, Inc. (PIRS)
ir.pieris.com [cached]
Mary Fitzgerald, Ph.D.
...
Mary Fitzgerald, Ph.D.
Vice President of Respiratory Medicine
Dr. Fitzgerald brings to Pieris more than thirty years of respiratory drug development experience. Prior to joining Pieris, Dr. Fitzgerald, from February 2010 was the Executive Vice President of Respiratory at Pulmagen Therapeutics and from November 2002 to February 2010, Dr. Fitzgerald held various positions at Etiologics, Ltd., formerly Argenta Discovery, most recently as Executive Vice President of Respiratory, where she was responsible for clinical development of inhaled and oral drug candidates for both COPD and asthma. Previously, from 1988 to 2002 Dr. Fitzgerald was employed by Bayer Healthcare, as a Project Leader and later as Head of Pharmacology. Dr. Fitzgerald received her PhD from Sunderland University / Wellcome Laboratories and received her BSc Pharmacology from Bath University.
Mary Fitzgerald, Executive ...
www.smi-online.co.uk [cached]
Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.
Mary Fitzgerald, Executive ...
www.smi-online.co.uk [cached]
Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.
Mary Fitzgerald, Executive ...
www.smi-online.co.uk [cached]
Mary Fitzgerald, Executive VP Respiratory, Pulmagen
Mary Fitzgerald, PhD, is the Executive Vice President of Respiratory at Pulmagen Therapeutics, where she leads a multi-disciplinary team that specializes in pre-clinical safety, regulatory affairs, CMC and clinical operations. Dr Fitzgerald has been an Executive Director of Argenta/Pulmagen since 2004. She was also responsible for clinical development at Argenta from 2008 to 2010. Previously, Dr. Fitzgerald was with Bayer HealthCare for 14 years, latterly as Head of Pharmacology. She was also the Head of Pharmacology at Argenta for 6 years with responsibility for establishing disease relevant models of chronic respiratory disease. She has spent over 20 years in the pharmaceutical industry and her major interest is in the development of anti-inflammatory therapies for COPD, asthma and cystic fibrosis. She is currently involved in 4 inhaled anti-inflammatory programmes for COPD, including three programmes with the potential to switch on ICS in COPD and severe asthma. She is also involved in the clinical development of an oral CRTh2 antagonist for asthma which is currently in Phase II.
Other People with the name "Fitzgerald":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304